Drugs / Fluocinonide
Fluocinonide
also known as
Fluocinolide · Fluocinonida · Fluocinonide emulsified base · Lidex · Lidex-e · Metosyn · Metosyn fapg · NSC-101791 · +1 more
Other / unclassified targets NR3C1 via activation
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | VANOS | — | 2006-03-02 | fda.gov ↗ |
| Approved | US (FDA) | LIDEX | — | 1971-06-30 | fda.gov ↗ |
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT01469767 | Feb 2012 → Aug 2013 | atopic eczema | Wake Forest University | Completed | No outcome recorded |
| Phase 2 | NCT01422408 | Sep 2011 → Oct 2015 | breast carcinoma | OHSU Knight Cancer Institute | Completed | Met primary |
| Phase 2 | NCT00667589 | Jun 2008 → Dec 2010 | exanthem, hand-foot syndrome | Northwestern University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 42 trials | ||||||
| Phase 4 | NCT01049243 | Mar → Sep 2009 | atopic eczema | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00819507 | Jan 2009 → Jan 2010 | atopic eczema | Oregon Health and Science University | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06135805 | Aug 2023 → Feb 2024 | lichen planus, oral | University of Catania | Completed | No outcome recorded |
| — | NCT02301494 | Apr 2020 → Apr 2022 | mycosis fungoides | Rochester General Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| Comparator or background therapy3 trials | ||||||
| Phase 0 | NCT01802580 Background | Oct 2012 → Mar 2016 | psoriasis | Wake Forest University | Completed | No outcome recorded |
| Phase 1 | NCT06504160 Background | May 2025 → Dec 2026 expected | atopic eczema | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 4 | NCT04207931 Comparator | Apr 2018 → Nov 2026 expected | central centrifugal cicatricial alopecia | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-02-11 | Zydus Lifesciences Limited | Zydus receives final approval from the USFDA for Fluocinonide Cream USP, 0.1%. zyduslife.com ↗ |
| 2019-03-28 | Lupin Limited | Lupin launches Fluocinonide Ointment USP 0.05% lupin.com ↗ |
| 2017-08-01 | Lupin Limited | Lupin receives FDA approval for generic Lidex® Ointment lupin.com ↗ |
| 2014-01-14 | Perrigo Company | Perrigo Announces FDA Final Approval for Generic Version of Vanos® (Fluocinonide) Cream 0.1% perrigo.com ↗ |
| 2008-06-09 | Perrigo Company | Perrigo Confirms Filing for Generic Version of VANOS® perrigo.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluocinonide | “Fluocinonide cream 0.1% applied twice daily for 5 days.” NCT01469767 ↗9“Clobetasol, Betamethasone Dipropionate, or Fluocinonide” NCT04207931 ↗ |
| Known as | Fluocinolide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1501 ↗ |
| Known as | Fluocinonida | ChEMBL registry synonym — accepted as the source's own label CHEMBL1501 ↗ |
| Known as | Fluocinonide emulsified base | ChEMBL registry synonym — accepted as the source's own label CHEMBL1501 ↗ |
| Known as | Lidex | ChEMBL registry synonym — accepted as the source's own label CHEMBL1501 ↗ |
| Known as | Lidex-e | ChEMBL registry synonym — accepted as the source's own label CHEMBL1501 ↗ |
| Known as | Metosyn | ChEMBL registry synonym — accepted as the source's own label CHEMBL1501 ↗ |
| Known as | Metosyn fapg | ChEMBL registry synonym — accepted as the source's own label CHEMBL1501 ↗ |
| Known as | NSC-101791 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1501 ↗ |
| Known as | Vanos | ChEMBL registry synonym — accepted as the source's own label CHEMBL1501 ↗ |
| Action | Activate | “Glucocorticoid receptor agonist” CHEMBL1501 ↗ |
| Modality | Other / unclassified | “a super-potent topical steroid cream” NCT00819507 ↗ |
| Route | Topical | “fluocinonide 0.05% cream applied twice per day to affected areas” NCT00667589 ↗ |
| Target | NR3C1 | “Glucocorticoid receptor agonist” CHEMBL1501 ↗ |